- Home
- TIL vs CRDF Comparison
TIL vs CRDF Comparison
Compare TIL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- CRDF
- Stock Information
- Founded
- TIL 2018
- CRDF 1999
- Country
- TIL United States
- CRDF United States
- Employees
- TIL N/A
- CRDF N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TIL Health Care
- CRDF Health Care
- Exchange
- TIL Nasdaq
- CRDF Nasdaq
- Market Cap
- TIL 171.7M
- CRDF 169.6M
- IPO Year
- TIL 2021
- CRDF N/A
- Fundamental
- Price
- TIL $26.95
- CRDF $3.35
- Analyst Decision
- TIL Buy
- CRDF Strong Buy
- Analyst Count
- TIL 5
- CRDF 4
- Target Price
- TIL $119.00
- CRDF $12.25
- AVG Volume (30 Days)
- TIL 316.4K
- CRDF 839.8K
- Earning Date
- TIL 05-13-2025
- CRDF 05-08-2025
- Dividend Yield
- TIL N/A
- CRDF N/A
- EPS Growth
- TIL N/A
- CRDF N/A
- EPS
- TIL N/A
- CRDF N/A
- Revenue
- TIL N/A
- CRDF $587,000.00
- Revenue This Year
- TIL N/A
- CRDF N/A
- Revenue Next Year
- TIL N/A
- CRDF N/A
- P/E Ratio
- TIL N/A
- CRDF N/A
- Revenue Growth
- TIL N/A
- CRDF N/A
- 52 Week Low
- TIL $9.62
- CRDF $2.01
- 52 Week High
- TIL $92.00
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- TIL 65.08
- CRDF 63.72
- Support Level
- TIL $12.60
- CRDF $2.81
- Resistance Level
- TIL $35.28
- CRDF $3.43
- Average True Range (ATR)
- TIL 3.84
- CRDF 0.19
- MACD
- TIL 1.60
- CRDF 0.08
- Stochastic Oscillator
- TIL 63.27
- CRDF 85.54
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.